Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients

Andrew David Badley, Robin Patel, Daniel F. Portela, William S. Harmsen, Thomas F. Smith, Duane M. Ilstrup, Jeffery L. Steers, Russell H. Wiesner, Carlos V. Paya

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disease and thus a guide for preemptive antiviral therapy, 126 consecutive liver transplant recipients were followed by routine CMV blood cultures in the absence of antiviral prophylaxis or treatment for viremia. Seventy-three patients (58%) developed CMV infections, and 36 (29%) had more than one infection episode: 29 patients (23%) had organ involvement and 45 (36%) had viremia. Within a same episode, CMV viremia was 90% sensitive and 80% specific for predicting concurrent organ involvement but preceded organ involvement in only 9 (31%) of 29 patients. In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was followed by organ involvement in a subsequent episode in 9 (33%) of 28 patients, mainly in the donor-positive, recipient-negative (D+/R-) population. The results indicate that CMV viremia is not an ideal marker to guide preemptive antiviral treatment in liver transplant recipients but is a good marker in D+/R- patients.

Original languageEnglish (US)
Pages (from-to)446-449
Number of pages4
JournalJournal of Infectious Diseases
Volume173
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Viremia
Cytomegalovirus
Liver
Antiviral Agents
Cytomegalovirus Infections
Transplant Recipients
Therapeutics
Tissue Donors
Infection
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Badley, A. D., Patel, R., Portela, D. F., Harmsen, W. S., Smith, T. F., Ilstrup, D. M., ... Paya, C. V. (1996). Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. Journal of Infectious Diseases, 173(2), 446-449.

Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. / Badley, Andrew David; Patel, Robin; Portela, Daniel F.; Harmsen, William S.; Smith, Thomas F.; Ilstrup, Duane M.; Steers, Jeffery L.; Wiesner, Russell H.; Paya, Carlos V.

In: Journal of Infectious Diseases, Vol. 173, No. 2, 1996, p. 446-449.

Research output: Contribution to journalArticle

Badley, AD, Patel, R, Portela, DF, Harmsen, WS, Smith, TF, Ilstrup, DM, Steers, JL, Wiesner, RH & Paya, CV 1996, 'Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients', Journal of Infectious Diseases, vol. 173, no. 2, pp. 446-449.
Badley, Andrew David ; Patel, Robin ; Portela, Daniel F. ; Harmsen, William S. ; Smith, Thomas F. ; Ilstrup, Duane M. ; Steers, Jeffery L. ; Wiesner, Russell H. ; Paya, Carlos V. / Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 2. pp. 446-449.
@article{3f19dcf900ce496baec2afd39aea2aae,
title = "Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients",
abstract = "To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disease and thus a guide for preemptive antiviral therapy, 126 consecutive liver transplant recipients were followed by routine CMV blood cultures in the absence of antiviral prophylaxis or treatment for viremia. Seventy-three patients (58{\%}) developed CMV infections, and 36 (29{\%}) had more than one infection episode: 29 patients (23{\%}) had organ involvement and 45 (36{\%}) had viremia. Within a same episode, CMV viremia was 90{\%} sensitive and 80{\%} specific for predicting concurrent organ involvement but preceded organ involvement in only 9 (31{\%}) of 29 patients. In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was followed by organ involvement in a subsequent episode in 9 (33{\%}) of 28 patients, mainly in the donor-positive, recipient-negative (D+/R-) population. The results indicate that CMV viremia is not an ideal marker to guide preemptive antiviral treatment in liver transplant recipients but is a good marker in D+/R- patients.",
author = "Badley, {Andrew David} and Robin Patel and Portela, {Daniel F.} and Harmsen, {William S.} and Smith, {Thomas F.} and Ilstrup, {Duane M.} and Steers, {Jeffery L.} and Wiesner, {Russell H.} and Paya, {Carlos V.}",
year = "1996",
language = "English (US)",
volume = "173",
pages = "446--449",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients

AU - Badley, Andrew David

AU - Patel, Robin

AU - Portela, Daniel F.

AU - Harmsen, William S.

AU - Smith, Thomas F.

AU - Ilstrup, Duane M.

AU - Steers, Jeffery L.

AU - Wiesner, Russell H.

AU - Paya, Carlos V.

PY - 1996

Y1 - 1996

N2 - To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disease and thus a guide for preemptive antiviral therapy, 126 consecutive liver transplant recipients were followed by routine CMV blood cultures in the absence of antiviral prophylaxis or treatment for viremia. Seventy-three patients (58%) developed CMV infections, and 36 (29%) had more than one infection episode: 29 patients (23%) had organ involvement and 45 (36%) had viremia. Within a same episode, CMV viremia was 90% sensitive and 80% specific for predicting concurrent organ involvement but preceded organ involvement in only 9 (31%) of 29 patients. In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was followed by organ involvement in a subsequent episode in 9 (33%) of 28 patients, mainly in the donor-positive, recipient-negative (D+/R-) population. The results indicate that CMV viremia is not an ideal marker to guide preemptive antiviral treatment in liver transplant recipients but is a good marker in D+/R- patients.

AB - To study whether cytomegalovirus (CMV) viremia is a reliable marker of impending CMV disease and thus a guide for preemptive antiviral therapy, 126 consecutive liver transplant recipients were followed by routine CMV blood cultures in the absence of antiviral prophylaxis or treatment for viremia. Seventy-three patients (58%) developed CMV infections, and 36 (29%) had more than one infection episode: 29 patients (23%) had organ involvement and 45 (36%) had viremia. Within a same episode, CMV viremia was 90% sensitive and 80% specific for predicting concurrent organ involvement but preceded organ involvement in only 9 (31%) of 29 patients. In a separate analysis, untreated isolated CMV viremia in the first CMV infection episode was followed by organ involvement in a subsequent episode in 9 (33%) of 28 patients, mainly in the donor-positive, recipient-negative (D+/R-) population. The results indicate that CMV viremia is not an ideal marker to guide preemptive antiviral treatment in liver transplant recipients but is a good marker in D+/R- patients.

UR - http://www.scopus.com/inward/record.url?scp=0030054164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030054164&partnerID=8YFLogxK

M3 - Article

C2 - 8568308

AN - SCOPUS:0030054164

VL - 173

SP - 446

EP - 449

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -